|
|
|
| Comparison of Two Antiplatelet Regimens in the Treatment of Clopidogrel Resistant Acute Coronary Syndrome |
| HONG Wei-jie, SHI Jun-ting |
| Department of cardiology, the Central Hospital of China National Petroleum Corporation Langfang ,Hebei 065000 |
|
|
|
|
Abstract 【Objective】 To investigate the clinical efficacy of different antiplatelet drug therapy in clopidogrel resistant patients with acute coronary syndrome (ACS).【Methods】 From July 2015 to June 2017, 220 ACS patients with clopidogrel resistance were selected. All patients received percutaneous coronary intervention (PCI). They were randomly divided into observation group and control group with 110 cases in each group. The control group was treated with clopidogrel + aspirin + cilostazol and the observation group with tigrilol + aspirin. The clinical efficacy and safety of the two treatments were compared.【Results】 There was no significant difference in platelet inhibition rate induced by adenosine diphosphate (ADP), arachidonic acid (AA) between the two groups (all P>0.05). The platelet inhibition rate of the ADP pathway in the observation group was significantly lower than that in the control group at 1 and 6 months postoperatively (P<0.05). The incidence of cardiovascular death, myocardial infarction and recurrent angina pectoris in the observation group was lower than that in the control group, and the incidence of thrombus in stent was higher than that in the control group, but there was no significant difference between the two groups (P>0.05). There was no significant difference between the two groups in the occurrence of severe bleeding, slight hemorrhage, rash, gastrointestinal reaction, thrombocytopenia and dyspnea (P>0.05).【Conclusion】 The therapy of ACS patients with clopidogrel resistance by aspirin, cilostazol and clopidogrel, or tigrilol as a replacement of clopidogrel has good clinical efficacy and good safety.
|
|
Received: 26 June 2018
|
|
|
|
|
|
[1] 韩敏珍,刘倩,兰雪,等.CYP2C19*1、*2基因多态性与氯吡格雷抵抗相关性的系统评价[J].中国医院药学杂志,2018(5):1-5.
[2] 刘永真.急性冠状动脉综合征介入术前后应用替格瑞洛对术后患者临床预后的影响[J].现代医药卫生,2018,34(1):77-79.
[3] 李晓红,杨明,韩凌,等.替格瑞洛及氯吡格雷对急性冠脉综合征介入治疗后的疗效比较[J].武警医学,2018,29(1):14-16.
[4] 李军,代满荣.替格瑞洛联合比伐卢定在ST段抬高型心肌梗死患者直接经皮冠状动脉介入治疗中的作用[J].中国药物经济学,2018,13(1):87-89.
[5] 陶涛涛,郑珂,黄睿等.细胞色素P450 2C19基因多态性与氯吡格雷抵抗及脑梗死预防的疗效观察[J].中华老年心脑血管病杂志,2018,20(1):88-90.
[6] 许骥,华琦,胡少东,等.替格瑞洛在老年STEMI患者急诊PCI中的疗效与安全性分析[J].首都医科大学学报,2015,36(1):73-76.
[7] 周佳子.替格瑞洛与氯吡格雷对冠心病患者PCI术后血小板功能及长期预后的影响对比分析[J].四川生理科学杂志,2018,40(1):1-6.
[8] 张越.经皮冠状动脉药物洗脱支架植入术后利用影响氯吡格雷代谢基因分型指导其个体化用药[J].实用医技杂志,2017,24(3):325-327.
[9] 李丽,曹学彬,石妍,等.替格瑞洛和氯吡格雷抗血小板治疗急性冠脉综合征的近期疗效和安全性比较[J].医学临床研究,2016,33(7):1385-1387.
[10] 刘利龙,崔静茹,宋佳,等.P2Y12基因多态性与心脑血管病患者氯吡格雷临床疗效相关性的Meta分析[J].中国药师,2017,20(11):1999-2003.
[11] 梁欣,陈世财,夏彬彬,等.细胞色素P450 2C19、PON1及ABCB1基因多态性与氯吡格雷抵抗的关联分析[J].中国临床药理学杂志,2017,33(7):585-588. |
|
|
|
2018, Vol. 35 
